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Introduction
Background of Parkinson’s diseaseParkinson’s disease (PD)  is the second most common neurodegenerative disorder, with a prevalence of 100 to 180 per 100,000 people [1] and over 10 million patients worldwide [2]. In the UK, 1 in 500 people suffer from PD and at least one person is diagnosed with this disease every hour. PD mostly affects people aged above 50 years but about 1 in 20 people with this disease is aged under 40 [3]. Genetic predisposition and environmental toxins are both putative risk factors for the disease. Pathological changes in PD may be present as early as 30 years before patients showing any signs that could allow diagnosis [4,5]. The primary lesion of PD involves degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta, causing dopamine 
deficiency within the basal ganglia. This leads to impaired motor function such as tremor at rest, dysphagia and abnormal gait [5]. However, there is a significant body of evidence suggesting that PD is more than just nigrostriatal dopamine 
deficiency [6,7]. Alongside dopamine depletion, Lewy body pathology is another 
hallmark of PD [5,8]. Aggregates of alpha-synuclein (α-SYN) are deposited within 
the cell body as Lewy bodies (LB) and within neurites as Lewy neurites (LN) [5]. Current therapeutic strategies for PD are pharmacological or surgical (deep brain stimulation). Traditional Pharmaco-therapy of PD is based on replenishing or sustaining 
dopamine levels. Levodopa (L-DOPA), a precursor of dopamine, still remains a frontier in this category [9]. However, with an increasing knowledge of the pathological 
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Abstract
Background: Parkinson’s disease (PD) is a chronic neurological disorder that impairs 
normal motor function and has no cure at present. Diagnosis of PD is clinical only; biopsies 
confirming the presence of the disease can only be done post-mortem. Furthermore, 
similarities in the manifestation of PD symptoms to other diseases such as Multiple System 
Atrophy (MSA), make early diagnosis difficult and ambiguous.  As a result, there is a high 
demand for research investigating biomarkers for timely diagnosis of PD. 
Alpha-synuclein (α-SYN) is a protein found misfolded in the brain and other body 
tissues of PD patients. Its relevance and association to PD make it a prime biomarker 
candidate. However, reports in the literature suggest that the structural form and location of 
α-SYN are key to yield a reliable diagnosis. The aim of this Minireview is to highlight efforts 
made in studying α-SYN as a biomarker over the past decade.
Key Findings: Based on the literature surveyed, α-SYN was indeed the most widely 
studied candidate biomarker for PD. Cerebrospinal fluid (CSF) and skin were promising 
sites for assessing α-SYN effectiveness in differentiating PD from MSA. Furthermore, 
gastro-intestinal α-SYN was suitable for early diagnosis of PD. A combination of total α-SYN 
and other forms including but not limited to phosphorylated α-SYN were the best predictors 
of the disease. 
Conclusion: Misdiagnosis of patients enrolled in clinical trials is a confounding factor 
for PD drug development. A robust biomarker for PD will help eradicate this problem. 
Identifying an accurate biomarker for PD will also ensure timely therapeutic intervention to 
manage symptoms better and improve the quality of life of patients. The promise α-SYN 
and its phosphorylated form show in different tissues is a step forward in this direction.
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mechanisms of PD, a gamut of therapies are under trial. Antioxidants such as coenzyme Q10 have shown neuroprotection 
in this regard [10]. Agents reducing inflammation such as minocycline are also under trial [11].
Currently, the diagnosis of PD depends on the identification of motor symptoms, which include bradykinesia, resting tremor and muscle rigidity [12]. However, PD patients suffer not only 
from motor symptoms, but also non-motor symptoms. Non-motor symptoms, such as rapid eye movement (REM) sleeping disorder, anosmia, constipation, mood disorders, and cognitive impairment are likewise well-recognised key features of PD 
[3,13,14]. Some of these non-motor symptoms may be present before the motor symptoms and often predominate as the disease 
progresses [5,7,15,16].
The need for biomarkers for PD and current strategies
The accuracy of the clinical diagnosis of PD ranges from 46% 
to 90%, being particularly poor in early stages of the disease 
[17-20]. Clinical diagnosis depends upon symptomatic features, which increases the risk of misdiagnosis in PD due to the fact that these symptoms present similarly in other diseases. In addition, 
there are only around 30% of neurons left when the symptoms become noticeable [3]. As a result, therapeutic intervention is delayed. Ideally a biomarker based diagnosis could help discover new targets for treatment and manage symptoms better, improve quality of life and reduce societal burden of the disease [21]. 
A biomarker is defined as “any substance, structure, or process that can be measured in the body or its products 
and influence or predict the incidence of outcome or after disease”[22]. This suggests that a biomarker for PD can either be based on imaging techniques or biochemical measurements. A robust biomarker should therefore be: non-invasive to acquire, 
convenient to measure, sensitive and specific. In addition, it is crucial to produce consistent and reliable data. Ideally, its level should change with disease progression and be useful even for patients in preclinical phases to allow progress monitoring and early diagnosis.
α-SYN, DJ-1, β-amyloid and tau present in CSF, and urate in blood are considered as optimal diagnostic biomarkers of PD 
[20]. DJ-1, β-amyloid and tau have shown association with PD. Mutations in the DJ-1 gene contribute to the incidence of early-onset familial PD. The primary function of the cellular protein 
DJ-1 is attributed to its defense against reactive oxygen species 
[23]. Presence of neurofibrillary tangles and β-amyloid plaques are features closely associated with Alzheimer’s disease. However studies have also shown the prevalence of these in PD, with a greater link to Parkinson’s disease dementia (PDD) [24].
Other compounds, such as heart-type fatty acid-binding 
protein (H-FABP), hypocretin, homocysteine and osteopontin are also candidate biomarkers of PD. There are also studies on tissue transglutaminase and serpins, which are suggested to have an 
association with α-SYN aggregation. MicroRNA 19b has been shown to correlate with patients having rapid eye movement (REM) sleeping 
disorder before synucleopathy diagnosis [25]. Neurotransmitter 
metabolites [26], such as homovanillic acid (HVA) and methoxy-hydroxy-phenyl-ethylene glycol (MHPG), growth hormones and amino acids which are associated with nitrogen monoxide and metals, e.g. iron and zinc, are all under research to assess their 
potential links with PD [27]. However, the studies involving these candidate markers are very preliminary and the results are 
inconsistent [27]. Among all of these potential biomarkers, α-SYN is considered to be the most promising biomarker. As a hallmark of 
PD, α-SYN attracts great interest to identify its potential usefulness in diagnosis and/or treatment of PD [28]. 
The importance of α-SYN
α-SYN is a 140-amino-acid protein, which is one of the three-
protein family comprising β-SYN, γ-SYN and α-SYN in humans [29]. While its normal physiological role still remains ambiguous, docking of synaptic vesicles, serving as a molecular chaperone, and maintenance of polyunsaturated fatty acid levels in the brain are among some of its reported functions [30]. Recent evidence 
also proposes a protective role of α-SYN against infectious agents 
in the central nervous system (CNS), wherein neurons were more 
susceptible to certain species of RNA viruses in α-SYN knockout 
mice [31]. Another study proposed the role of α-SYN in normal 
functioning of the nigrostriatal system. A deficiency in striatal 
dopamine and loss of locomotor function was seen in α-SYN knockout mice [32]. Perez et al. also demonstrated the ability 
of overexpressed α-SYN to reduce tyrosine hydroxylase activity 
in- vitro, consequently interfering with dopamine synthesis [33]. 
Overexpression of mutant α-SYN also reduced the dopamine storage pool, leading to impaired motor function in transgenic mice [34] and subsequently increasing cytoplasmic dopamine, leading to its oxidation in-vitro [35]. α-SYN also plays a role in 
modulating the human dopamine transporter. Lee and colleagues show that this results in intracellular uptake of dopamine, leading 
to apoptosis [36].
LBs are widespread in nature, present throughout the brain, spinal cord, peripheral nervous system, enteric nervous system, salivary glands, adrenal medulla, cutaneous nerves and sciatic 
nerve. Braak et al. have proposed the prevailing theory that 
in early stages Lewy pathology is seen in regions of the brain 
stem, ultimately spreading to the midbrain and cortex [37]. Highlighting the involvement of the gastric system further is the 
“dual-hit hypothesis”, which accounts for the early presence of 
Lewy pathology seen in this region. This hypothesis proposes initiation of PD by a pathogen, possibly entering the body via nasal and gastric routes [38]. This theory might be further enhanced 
by Braak and colleagues who successfully demonstrated that 
inclusions of α-SYN are present in innervations to the gastro-intestinal (GI) tract [39]. Recent evidence has furthermore shown the gut micro biome to play a role in PD pathology [40]. Therefore, 
we see that there is an active involvement of the GI tract in Lewy body pathology.
Oligomeric and fibrillar α-SYN are formed from the 
aggregation of α-SYN via different pathways and due to different 
factors, such as phosphorylation on specific sites [41], addition of metal ions and small charged molecules [42], and mutations [43]. Conformations and aggregation states (soluble oligomers, 
amorphous aggregates or amyloid-like fibrils) of α-SYN vary depending on the conditions and co-factors [44]. Although several 
aggregation states of α-SYN may be neurotoxic, the oligomeric form is suggested to be highly correlated with neurotoxicity [45]. 
While the native structure of α-SYN remains unclear, there are 
studies hinting at either the monomeric [46,47] or alpha-helical 
tetrameric [48] as the physiological form. Since α-SYN is found 
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in various regions of the body and in different forms, several discrepancies about its potential as a biomarker for PD remain. The aim of this review is to examine the literature focusing 
on α-SYN as a biomarker for PD, compared to other molecules. 
The biomarker potential of α-SYN for PD is then evaluated with an emphasis on the sites where it is found.
Methods
Identification of studies for the minireview
For the purpose of this Minireview near 100 publications 
were examined after following strict criteria. Studies were 
identified by searching electronic databases, i.e., Embase and 
PubMed. The free text and MeSH terms used in this search were 
“PD”, “alpha-SYN” and “biomarkers”. The last search was run on 2nd December 2016. Other searches in PubMed included the 
following combinations, in which the free text and MeSH terms 
of “PD”, “biomarkers” and (a) “tau” or “tau protein”; (b) “DJ-1” 
or “DJ protein”; (c) “amyloid-b” or “amyloid beta”; (d) “uric acid” 
or “urate” were used to retrieve the number of papers which 
are studying these biomarkers. Another “PD”, “biomarkers” and 
(a) “plasma”; (b) “saliva” or “salivary gland” or “submandibular 
gland”; (c) “gastrointestinal tract” or “stomach” or “colon”; 
(d) “skin”; (e) “cerebrospinal fluid” to identify the number of 
publications per biological matrix. The last search was “PD”, 
“alpha-SYN”, “biomarkers” and (a) “oligomer” or “oligomeric”; (b) 
“phosphorylated”; (c) “monomer” or “monomeric”; (d) “native” to identify the number of papers which were published per forms 
of α-SYN. 
Only studies involving human participants were included; 
any animal studies were excluded. Studies published in English language in the top 50 journals on the subject area 
of “Neuroscience” and top 200 journals on the subject area 
of “Biochemistry, Genetics and Molecular Biology” ranked by 
SC imago Journal & Country Rank [49] were selected. Also a restriction on year of publication was applied to the last ten years 
(2006-2016) and any review articles identified from the search were excluded.
Results and Discussion
α-SYN and other potential biomarkers for PDA considerable difference in the literature published between 
α-SYN and other main potential PD biomarkers, including tau, 
β-amyloid, DJ-1 and uric acid was observed (Figure 1). Till date, 
the number of publications studying α-SYN has reached 324, which is at least twice as much as the other candidates according to the database search (see Methods). In addition, it is apparent that 
there has been a rapid rise in number of publications on α-SYN (a 
two-fold increase) over the last five years (Figure 1). This is closely 
followed by tau and β-amyloid, for which the number of papers 
published in the past five years were almost double in comparison 
with the amount of papers available from 2006 to 2010 (Figure 1). 
Considering these trends, a growing interest in the roles of α-SYN for the diagnosis of PD was clearly observed.
Locations and conformations of α-SYN as a potential 
PD biomarker
α-SYN was detected in various places of the body. Based 
on the data retrieved from the PubMed search, cerebrospinal 
fluid (CSF), plasma, GI tract, saliva and related glands, and skin were studied in recent investigations. There is a vast amount of 
literature focusing on CSF α-SYN, having 83 papers published 
in the last ten years with a threefold increase over the last five 
years (Figure 2). Publications discussing the GI tract increased 
greatly from 2 to 22 papers over a five-year period (Figure 2). Remarkable growth on this area leads us to believe it is another considerable site for future tests. In contrast, the numbers of 
publications concerning plasma in the past five years (8 papers) 
were the least, greatly overtaken by the GI tract (Figure 2). It also 
seems that researchers have started exploring the significance 
of salivary and cutaneous α-SYN with a gradual increase in the number of studies. However, reports are still rare with only 14 
and 12 publications respectively, over these ten years (Figure 
2). Overall, it is evident that experts are intensively studying CSF 
α-SYN in comparison with other biological matrices. Meanwhile, the potential of other sites are yet to be fully explored. 
Trends in the forms of α-SYN as biomarkers was also looked 
Figure 1. The number of papers studying the potential of α-SYN, tau, 
amyloid beta, DJ-1 and uric acid as PD biomarkers, published in the last ten 
years (2006 – 2016).
Sampling material
Figure 2. The number of papers studying α-SYN in different locations, 
including cerebrospinal fluid, gastrointestinal tract, plasma, saliva, and 
salivary glands and skin, published in the last ten years (2006 – 2016).
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into. Most researchers focus on total α-SYN in their studies (61 papers), closely followed by phosphorylated forms with just 9 
papers less (Figure 3). The phosphorylated form, predominantly at serine 129, seems to be the most popular focus in comparison 
with all the other forms (Figure 3). Phosphorylated α-SYN 
(p-α-SYN) is widely recognised as the pathological form of PD [50]. This might have directed the interest of experts towards phosphorylated species.
Potential of α-SYN in Cerebrospinal Fluid (CSF) as a 
biomarker
PD vs. other neurological conditions: In a large study, Mollenhauer et al. detected the total concentration of α-SYN 
by using ELISA and Western blotting [51]. Their results could distinguish PD from Alzheimer’s disease (AD) and non-
synucleopathies, including Progressive Supranuclear Palsy (PSP) 
and Normal-pressure Hydrophalus (NPH), with a sensitivity and 
specificity of 70.72% and 52.83% respectively. Their results 
match the findings of Hall and colleagues who also observed a 
decrease in CSF α-SYN in PD and other parkinsonian disorders 
when compared to AD [52]. Furthermore, a combination of α-SYN and other AD biomarkers, including total tau, phosphorylated tau 
(p-tau), and Aβ1-42 has been proposed to differentiate PD and AD 
[52]. A sensitivity of 93% and specificity of 84% was achieved 
when using the combination of α-SYN and Aβ1-42, the fragment 
of β-amyloid abundant in AD patients, as an additional indicator 
[53]. Concentration of oligomers and the ratio of oligomeric α-SYN 
to total α-SYN (o/t-α-SYN) were higher in Parkinson’s disease with dementia (PDD) patients when compared with subjects with 
AD, but with lower diagnostic accuracy than total α-SYN [54]. This is in accordance with another study, proving the possible 
use of oligomers to differentiate PD from AD and PSP [55]. Wang 
and colleagues recommended the use of a combination of p-α-
SYN and total α-SYN to distinguish PD from MSA and PSP [56]. 
In contrast, the study by Foulds et al. did not show appreciable 
differences in total α-SYN concentrations between PD and PSP in 
a post-mortem study [57]. 
A high degree of concordance in total α-SYN concentration 
between PD and MSA was reported in a small number of studies 
[51-53,57]. Levels of oligomeric and phosphorylated forms did not 
show significant difference among these two groups of subjects in the post mortem study [57]. Oligomeric phosphorylated 
α-SYN (o-p-α-SYN) was found useful in this study, being able 
to distinguish PD from MSA and other neurological patients, 
including PSP and DLB. Also, Shi and colleagues noticed a more 
significant reduction of oligomeric phosphorylated species in 
MSA when compared to PD cases [53]. 
PD vs. Controls: The results of these studies [52,53,56,58-
63] showed a significant decrease in total concentrations of 
α-SYN in PD compared to healthy controls with a specificity of 
25% -75.7% [53,59,63,64] and generally high sensitivity of 92%-
100% [53,59,63], except one report that showed a relatively 
low sensitivity (63%) [64]. Unlike total α-SYN, levels of p-α-SYN 
[57,58] and o-α-SYN [54,55,58,64] were found to be higher in PD. 
By studying o/t- α-SYN instead of oligomers alone, Tokuda et al. 
claimed that sensitivity and specificity were improved from 75% 
to 89.3% and 87.5% to 90.6% respectively [55]. A study carried out by Parnetti et al., however, demonstrated increased specificity 
from 41.6% to 85.7% but a poorer sensitivity of 56.2% by 
analysing o/t-α-SYN instead of o-α-SYN [64]. Besides, combining 
p-α-SYN and total α-SYN together also gave better performance 
than using the phosphorylated form only [56]. However, the 
study undertaken by Foulds and colleagues again found no differences in the levels of these forms between PD and controls, 
but was suggestive of the ability of o-p-α-SYN in differentiating 
PD patients from healthy controls [57]. It must be noted that the 
conflicting results showing no noteworthy difference in levels of 
α-SYN in all individuals, except o-p-α-SYN, were obtained from the only post mortem study [57]. 
Combination of α-SYN and other biomarkers: There are 
few CSF studies supporting the theory that a combination of 
α-SYN with other biomarkers could improve the diagnostic ac-
curacy of PD. For example, a study conducted by Shi et al., re-
vealed the possibility of distinguishing PD from AD, MSA and also 
healthy controls by using seven biomarkers including α-SYN [53]. 
This finding is vital as the similarities in clinical manifestations 
between MSA and PD are a major problem for differential diag-
nosis, while α-SYN per se is inadequate to work as a biomarker. 
In addition, higher sensitivity (90%) and specificity (71%) could 
be achieved by using a combination of α-SYN and p-tau to dis-
tinguish PD from MSA [53]. Besides, distinctions between synu-cleopathies and tauopathies could be made by using the ratios of 
total tau to α-SYN (t-tau/α-SYN) or p-tau/α-SYN [59]. t-tau/-SYN could also determine PD from other neurological conditions, i.e., primary headache, post-infective myelopathy, and polyneuropa-
thy with high sensitivity of 89% and specificity of 61% [59]. The 
combination of p-tau with o/t-α-SYN or p-α-SYN also allows bet-ter discrimination between PD and healthy controls [58]. Thus there are strong evidences in literature which highlight combina-
tions of different CSF biomarkers as a promising strategy to im-prove diagnostic accuracy for PD.
Correlation of α-SYN with Age, Treatment, Disease Sever-
ity and Disease Duration: Overall, different forms of CSF α-SYN 
have no correlation with age [52,59,65]. Treatments likewise 
showed no effects on α-SYN levels [51,61,63]. These results may 
suggest that changes in CSF α-SYN levels are solely due to the pa-thology of PD. 
 Total number of publications = 132
Figure 3. The number of papers studying different forms of α-SYN i.e., 
native, oligomeric, monomeric phosphorylated and total α-SYN, published 
within the last ten years (2006 – 2016).
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A small number of studies were performed to identify the 
possible link of α-SYN with disease progression. The increase 
in pattern of total and o-α-SYN found in longitudinal studies 
supports the potential of CSF α-SYN serving as a biomarker for 
disease progression [61,66]. Interestingly, Hall and colleagues noticed that the correlation pattern was not observed in the 
cases of PD for less than or equal to five years [66]. In contrast 
with the patterns observed in total and o-α-SYN, Majbour et al. 
noticed an obvious reduction in p-α-SYN concentration when 
compared to baseline level [61]. However, Stewart et al. detected 
an opposite longitudinal trend in p-α-SYN levels in PD subjects 
[65]. This could be due to disease stages of PD subjects studied. 
Levels of p-α-SYN were suggested to decrease during the early 
stages but increase at the later stages [65]. This explains the 
converse findings of both studies as all PD subjects in Majbour et 
al. research were at initial disease stages. A study conducted over two years suggested that higher levels 
of α-SYN within PD may indicate faster progression of motor 
symptoms and cognitive impairment [60]. Two cross-sectional 
studies, however, found converse correlation of α-SYN [62] or 
those in oligomeric form [58] with motor symptoms [65]. 
On the other hand, Hong et al. and Stewart et al. both showed a 
lack of correlation between α-SYN levels and PD progression [65]. It is worthy to mention that the post-mortem study conducted 
by Fould et al.  reported similar findings, suggesting the lack of 
correlation between total α-SYN, o-α-SYN, p-α-SYN and o-p-α-SYN 
with disease severity [57]. Moreover, no correlation was found 
between α-SYN and disease duration [51,54,57,59].
Potential of α-SYN in GI tract as a biomarker 
PD vs. Other Neurological Conditions: The patterns of 
α-SYN in gastric and colonic mucosa detected in PD and MSA were reported to be similar using immunohistochemical techniques 
[67]. However, this was not the case for AD patients with LBs. 
While the PD group showed more than a 60% frequency in 
cases showing positive staining for p-α-SYN, the AD group had a 
frequency of less than 20% [68].
PD vs. Controls: Besides PD patients, total [67,69-72] or p-α-
SYN [70,72,73] immunostaining were likewise found positive in the study controls, whilst there are few studies showing positive 
immunostaining for total [73-76] and p-α-SYN [77,78] in PD 
subjects but not in controls. The study conducted by Sánchez-
Ferro et al. [79] reported that only 2 out of 29 controls showed 
the presence of α-SYN [79]. Although α-SYN was expressed in both PD and controls in a study set up by Gold and colleagues, 
the frequency and intensity of α-SYN expression were much higher in PD, suggesting its usefulness in differentiating PD 
patients from controls [80]. α-SYN immunostaining was positive 
in 100% of the PD subjects in three of these studies [74,76,81]. 
Besides identifying α-SYN in all nine PD individuals of the study 
conducted by Shannon and colleagues [74], it was also present in normal control subjects and ulcerative colitis patients but with a 
distinct pattern and low percentage, 8% and 23% respectively. 
Studies with 100% of α-SYN immunostaining in PD involved 
only 3-9 patients in total [74,81]. Despite the fact that none of 
the 161 controls in a large cohort study was found with α-SYN 
immunoreactivity, it is surprising that only 7 out of 62 PD 
patients showed accumulation of α-SYN [75]. These results 
lead us to believe that GI α-SYN may not be sensitive enough to 
use as a robust PD biomarker. The sensitivity and specificity of 
α-SYN reported in studies range between 36.1 -85%and 53.2-
95%, respectively. In addition, patients in early stages of PD [77], including individuals with biopsies taken before diagnosis  of PD 
[75,81] were investigated in a few separate studies. Detection 
of total and p-α-SYN immunostaining proved their possible 
usefulness for early diagnosis. By showing α-SYN as specifically present in subjects with preclinical PD, the large scale study conducted by Hilton et al. provides clear evidence to propose 
GI α-SYN as a specific early diagnostic biomarker for PD [75]. However, more studies with larger cohorts are needed to further support this hypothesis. 
Rostro-caudal gradient: α-SYN was found in different parts of 
the GI tract, including oesophagus [68], duodenum [68], jejunum 
[68], ileum [68], sigmoid colon [67-69,74,81], descending colon 
[78,81], transverse colon [67,68], ascending colon [67,77,78], 
rectum [68,69,78], rectosigmoid segment [72], upper digestive 
tract [76], appendix [71], fundus, antral and pyloric region of 
stomach [67,79]. By analysing immunoreactivity of α-SYN in 
the colon and rectum, α-SYN exhibited decreasing rostro-caudal 
gradient patterns [78]. This was in line with the findings of two 
other studies [67,68], however in contrast with a study having 
the most abundant and highest density of α-SYN in the appendix 
in comparison with stomach, ileum and colon [71]. The rostro-caudal gradient detected in various studies suggest that gastric 
biopsies may be a better choice for studying α-SYN accumulation for PD diagnosis. However, the potential of appendicular sites cannot be disregarded.
Submucosa vs. Mucosa: Among all studies, α-SYN was 
mostly found in submucosa [74,75,77,78,80,81] of PD patients, whereas some studies also detected its presence in mucosa 
[67,69,70,75,79]. For those studying the mucosa of subjects, α-SYN was not only detected in PD patients, but also in healthy controls 
[28,69-71,79]. This further suggests the lack of usefulness of mucosa for PD diagnosis. Although there is one study detecting 
α-SYN in the submucosa of neurologically intact patients [72], all 
the other studies reported high potential of submucosa α-SYN in differentiating PD from controls. Taken together, submucosal 
α-SYN, but not mucosal, was strongly believe to be a useful diagnostic tool for PD.
Correlation of α-SYN with age, disease severity and 
disease duration: Bottner et al. detected an increase in immuno-
reactive signals of p-α-SYN with increasing age while the native 
form of α-SYN remained the same [72]. Ali and colleagues 
observed a correlation between density and intensity of α-SYN 
and severity of disease [76]. 
Contrary to this, most studies suggest that α-SYN does not 
reflect the disease status [67,70,78],  duration [67] and is not 
related to age [72]. Chung and colleagues demonstrated that 
treatment has no effects on α-SYN [67].
Potential of α-SYN in blood as a biomarker
PD vs. Controls: A disparate pattern was observed 
regarding the presence of α-SYN in blood. A longitudinal study 
investigated the levels of p-α-SYN, total α-SYN, o-α-SYN and o-p-
α-SYN in plasma over a three-month period, using ELISA [82]. In comparison to healthy controls, the level of p-α-SYN was observed as most differentiated in PD, suggesting it might be a 
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better biomarker. The outcome was different from their previous 
study [83], which showed a statistically significant rise in o-α-
SYN levels in PD patients. This discordance might be explained by variations in control subjects recruited, detection systems and 
assay sensitivity. Another study detected elevated α-SYN in PD groups [84]. Interestingly, Papaiannakis and colleagues investigated 
monomeric and dimeric conformations of α-SYN in erythrocytes 
of PD patients [85]. Dimeric α-SYN was found to be significantly high in PD when compared to healthy controls. There was 
however, no difference in monomeric α-SYN levels in both PD and healthy subjects. This opens a new area of investigation 
for researchers to find out the potential of α-SYN dimers in PD diagnosis.
Correlation of α-SYN with Age, Treatment, Disease 
Severity and Disease Duration: In the study by Foulds and 
colleagues, p-α-SYN has no link with age, whereas other forms 
of α-SYN showed a weak correlation with age [82]. This is in 
agreement with other studies [84,86], reporting no association 
between PD patient age and total α-SYN and p-α-SYN. Duran et 
al. recruited PD subjects with and without treatments in a study, 
proving that the relatively high levels of α-SYN was not due to 
the medications used, supporting the usefulness of α-SYN as a biomarker for PD [84].
Although total α-SYN remains stable within the duration of 
the cohort studied by Foulds and colleagues, the short duration of this study (four months) may warrant further investigation 
[82]. In another longitudinal study, levels of total -SYN and p-α-
SYN were determined for up to four years [86]. Over this period, 
substantial elevation in total -SYN levels was observed, whereas 
p-α-SYN remained high with no longitudinal change. Results found by Duran et al. contradicted this, finding no relationship 
between α-SYN concentration and disease duration [84].
Potential of α-SYN in saliva and salivary glands as a 
biomarker
PD vs. Other neurological conditions & controls: There are 
discrepancies in the findings regarding the submandibular gland 
[68,87-89]. A post-mortem study successfully demonstrated the 
presence of α-SYN in all PD and 2 out of 3 incidental LB disease, 
i.e. prodromal PD patients, but not any α-SYN immunostaining 
in controls and MSA patients, suggesting its usefulness for early diagnosis with the caveat of being an invasive technique 
[87]. In contrast, Stewart et al. suggested that α-SYN level in PD was indistinguishable from controls [89]. Two independent 
studies [68,88] observed the most p-α-SYN in submandibular 
gland. Also, p-α-SYN was present in many more sections of PD 
submandibular gland when compared to AD [68]. However, no 
controls were recruited in one of the studies [88] for specificity validation.  In accordance, the post-mortem study conducted by 
Beach et al. demonstrated that p-α-SYN was mostly located in the submandibular gland and lower oesophagus in comparison with 
other parts of the GI system in PD [68]. However, it should be noted that most of these studies were explorative with less than 
50 subjects [87-91].
The presence of α-SYN in minor salivary gland has also been shown [88,90]. Although it was detected in 2 out of 3 PD cases but none of the 3 controls [90], its usefulness could not be validated 
as the subjects involved are insufficient to provide reliable and 
unbiased results. Furthermore, in one study, only 1 in 15 PD 
patients was identified with p-α-SYN in the minor salivary gland, showing its poor sensitivity [88]. Thus, minor salivary gland may not be an ideal site for PD diagnosis. 
In all 3 studies focusing on α-SYN in saliva [89,91,92], total 
α-SYN, showed no appreciable difference between PD and healthy controls. In fact, 2 out of 3 studies [91,92] noticed a slight 
reduction in α-SYN in PD when compared to controls but this was 
not significant enough to prove its usefulness. Instead, a high level 
of o-α-SYN was observed in the saliva of PD patients compared to controls, suggesting the potential of oligomeric form [92].
Correlation of α-SYN with Age, Treatment, Disease 
Severity and Disease Duration: Investigations by Kang and 
colleagues demonstrated that the level of total salivary α-SYN was 
not influenced by any kind of treatment, but negatively correlated with age in PD patients [92]. Another study does not agree with 
this finding, reporting no association between α-SYN and age [89].Kang et al. also found no correlation between disease 
duration and severity of motor symptoms with salivary α-SYN [92], whereas another study found a minor inverse relationship 
[91]. The potential of o-α-SYN as a biomarker of PD progression 
was corroborated by showing great differences at each Hoehn & 
Yahr stage [92]. 
Potential of α-SYN in skin as a biomarker
PD vs. Other neurological conditions: Although 
immunostaining of p-α-SYN distinguished PD patients well from individuals with tauopathies and normal controls, sensitivity 
was the same in MSA cases [93]. Different locations of p-α-SYN 
staining in PD and MSA, however, allowed these two groups to be 
distinguishable. It was found present in autonomic fibres in PD, 
but in somatosensory fibres in MSA. This was further confirmed by Zange and colleagues [94].
PD vs. Controls: Good specificity was observed with cutaneous 
α-SYN as none of the healthy controls showed immunostaining 
for total or p-α-SYN [93-97]. However, p-α-SYN was only found in 
51% of PD subjects in another study [95]. This could be justified by the immunohistochemical technique applied, which is less sensitive, and the difference in skin thickness analysed. This 
hypothesis was confirmed by Donadio and colleagues, proving 
that p-α-SYN staining could be affected by sample thickness in 
their studies [96]. A study by Wang et al. detected α-SYN in both PD and healthy subjects with higher deposition in PD patients [98]. 
Five of the six studies used skin biopsies of proximal and distal regions of the leg [93,95-98]. Their results were in high concordance with each other, suggesting that detection of 
α-SYN from skin biopsies of leg and thigh might be a robust PD 
biomarker. In addition, no positive p-α-SYN staining was found in the abdominal skin of any of the PD patients in a post-mortem study [90]. This may be due to the difference of biopsy sites taken, suggesting the relative limited usefulness of abdominal sites when compared to legs and thighs. Interestingly, Donadio and colleagues studied the native form 
of α-SYN in skin nerve fibres [96]. A similar expression pattern of 
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α-SYN was observed in PD and control subjects. Thus, this form might be not a useful diagnostic tool.
A decreasing gradient in p-α-SYN deposition from proximal (sites on the back) to distal (distal portions of the leg) sites was 
found [93,95,96]. Both studies focused on the cervical sites 
showed 100% of α-SYN detection in PD patients [96,97]. 
Correlation of α-SYN with disease severity and disease 
duration: A correlation between α-SYN with PD severity was 
revealed [98], whereas, p-α-SYN was suggested to have no 
association with disease duration [94,96].
Comparison between potential of α-SYN on all sites
The biomarker potential of α-SYN in different biofluids and tissues has been summarised in table 1.
The importance of CSF for biomarker studies simply cannot 
be overstated. Its proximity to the CNS, and the functional role 
it plays in clearing the CNS of pathogenic material make it an important asset. However, the invasive techniques used to obtain 
CSF samples make it a less convenient method. In addition, slight 
contamination of blood in CSF can lead to a great elevation of 
CSF α-SYN levels, giving a false result. Although no correlation 
between α-SYN levels and haemoglobin levels was suggested by some authors, a lot of evidence demonstrates otherwise 
[62,63,99]. Hong and colleagues [63] found no statistical 
difference in α-SYN levels of PD and controls when high levels 
of haemoglobin were permitted [63]. Also, CSF α-SYN levels was modestly increased when haemoglobin contamination was 
more than 1000 ng/mL [62]. Although the authors claimed that levels of haemoglobin were similar among all subject groups, the assumption might be misleading as the levels had a wide range 
from 4400 - 6100ng/mL in their cohort. Lastly, CSF α-SYN might 
not be the most suitable candidate for a longitudinal biomarker when taking accessibility into account. 
GI -SYN seems to be an ideal tool for early diagnosis, but the 
major limitation is its inconsistent sensitivity and specificity 
among different studies. GI α-SYN also seemed to show no association with disease duration or status. Therefore, it might not be an ideal biomarker for disease progression. It is noteworthy 
that sensitivity of sub mucosal α-SYN was better than mucosal 
α-SYN as shown by some studies [78,79,81]. 
Collection of blood is less invasive compared with GI or CSF. Moreover, consistent results in regards to negative correlation of 
blood α-SYN with age and treatment act as mounting evidence of its promise for diagnosis.A high accessibility of saliva and low blood contamination risk make it an ideal candidate for disease progression monitoring. However, the salivary gland was more useful than saliva in differentiating PD from the healthy controls. Although the minor salivary gland proved to be inconclusive, the submandibular gland showed better promise in differentiating PD from AD and 
MSA. p-α-SYN was useful in differentiating PD subjects from MSA, 
based on its deposition in different nerve fibres. Furthermore, skin biopsies taken from the proximal portions of the legs and 
back were shown to be the most efficacious.  However there remains a need to standardise the methods of investigation as 
sensitivity and specificity are believed to be influenced by the number of sections and thickness of samples taken.
Current limitations and on-going effortsThe major limitations of current studies are the lack of standardisation on methodologies and outcome measures. This is commonly attributed to inter-laboratory discrepancies and 
Site Strengths Limitations
CSF
(1) Site with the most reproducible and consistent findings
(2) High sensitivity
(3) Direct reflection on disease states
(4) Relatively cheap in comparison with imaging biomarkers
(5) Combination of CSF biomarkers able to distinguish PD from AD and 
MSA
(1) Inadequate specificity
(2) Unable to access in most clinical settings
(3) Risk of false positive results due to blood contamination 
(4) Invasive method
GI tract
(1) Consistent findings in submucosa
(2) Relatively easy sampling method by using endoscopy
(3) Potential for early diagnosis
(1) Inconsistency of diagnostic accuracy due to rostro-caudal gradient
(2) Lack of usefulness on mucosa
(3) Relatively invasive




(3) Effective in differentiating PD patients from controls
(1) Inconsistent findings





(2) No risk of blood contamination
(3) Easy and direct collection methods
(4) Cost-effective
(5) Painless
(6) Ideal for longitudinal monitoring
Glands
(1) Able to be performed in out-patient
(2) Less invasive
(3) Submandibular gland is useful in detection of prodromal stages 
of PD
Saliva
(1) Lack of usefulness in differentiating PD from controls
Glands
(1) Lack of usefulness of minor salivary gland
(2) Side effects, e.g., swollen cheek and sore throat
Skin
(1) Accessible
(2) No risk of blood contamination
(3) Less invasive
(4) Consistent findings on the proximal sites of the leg
(5)  Ideal for longitudinal monitoring
(1) Difficulty with keeping sample thickness consistent.
(2) Abdominal sites not useful
Table 1.  Strengths and limitations of α-SYN as a PD biomarker in different sites of the body.
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leads to a lot of consequential problems on the validation of a biomarker for PD. The differences in assay methods, subjects 
recruited, α-SYN species and duration of studies, make it difficult to compare data all together. 
The absence of a standardised assay for α-SYN makes it 
difficult to identify well-defined sensitivity and specificity of 
α-SYN for diagnosis of PD.  Furthermore, a clear cut-off point of the 
diagnostic range of α-SYN level is still absent due to the varying results across laboratories. This is achievable if standardised protocols are set up and used across different studies. It is crucial 
to identify the upper or lower limits of normal α-SYN levels in 
different sites because this would allow α-SYN to provide true positive results accurately on the diagnosis of PD.To address this limitation, well-characterized methodologies, including number and types of subject recruited, clinical data 
acquisition, affinity of antibody, sampling methods, assay design 
and controlled variables need to be established. For sampling methods, it is recommended to collect more than one sample 
from each subject for assaying. For studies on skin and colon, thickness of samples should likewise be outlined. Methods of handling, storage and processing the samples would all affect 
study outcomes. Several standardized protocols for the collection 
and storage of CSF have been established, such as those during 
the BioMS-eu (2007) annual meeting [100]. Factors such as volume of collection and temperature of storage greatly affect the concentration and stability of biomarkers [100]. The type 
of needle used (atraumatic Sprotte or Whitacre) greatly affects 
patient comfort levels, in turn influencing compliance. Storage 
of the CSF should ideally be done in polypropylene tubes, which 
have the least protein binding affinity, and will thus influence 
α-SYN levels the least [100]. A small degree of contamination with red blood cells could 
easily affect the levels of α-SYN present in CSF and plasma. Thus, an acceptable range of blood contamination should be determined to allow consistent exclusion criteria in all future studies. Another example of important variables is the disease state and number of subjects recruited. A few programmes have been set up to resolve the challenges 
and speed up PD biomarker validation, such as Bio FIND [101] and 
The PD Biomarker Program (PDBP) [102]. A project supported 
by PDBP tries to evaluate all ranges of data and identify the patterns across different investigating sources. The Michael J. Fox 
Foundation (MJFF) has also funded grants to evaluate different 
assays and performance consistencies of α-SYN [103]. This can be 
done by sharing samples, reagents, methods and findings. After 
identifying the most powerful assay for α-SYN detection and 
quantification, it can then be used across different investigations and inter-laboratory data generated can be comparable. 
Conclusions & Future Perspectives
CSF α-SYN produced highly consistent results in different studies, and seems to be the most promising diagnostic biomarker for PD. However, the potential blood contamination 
and relatively invasive methods for obtaining CSF samples are 
its major drawbacks. Based on the very limited data currently available on this aspect, plasma might be a better option due to its great accessibility. The GI tract shows the most usefulness during pre-symptomatic stages. This is extremely important 
for PD, allowing intervention as soon as possible to minimize decline. Also, it is very encouraging to identify the potential of 
cutaneous p-α-SYN on differential diagnosis between PD and 
MSA. This is a big step forward in this field as it could barely be 
achieved by using traditional clinical diagnosis. Furthermore, a 
combination between α-SYN and other biomarkers such as Aβ1-42 are believed to be a better option to achieve optimum sensitivity 
and specificity.
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